Efficacy and Safety of Oral Spironolactone for Female Pattern Hair Loss in Premenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study

This study assessed the efficacy and safety of oral spironolactone (100 mg daily) combined with topical minoxidil for treating female pattern hair loss (FPHL) in premenopausal women. Conducted as a randomized, double-blind, placebo-controlled trial with 48 participants, it found that spironolactone significantly increased hair density and diameter, with improvements in total and terminal hair counts. However, irregular menstruation was a common side effect, affecting about one-third to 50% of users. Despite these side effects, spironolactone was generally well-tolerated and effective in promoting hair growth, suggesting it as an alternative treatment for mild-to-moderate FPHL. The study's limitations include a small sample size and short duration, indicating the need for further research.